8-K
Horizon Therapeutics Public Ltd Co 00-0000000 false 0001492426 0001492426 2022-04-28 2022-04-28

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 28, 2022

 

 

Horizon Therapeutics Public Limited Company

(Exact name of registrant as specified in its charter)

 

 

 

Ireland   001-35238   Not Applicable

(State or other jurisdiction

of incorporation)

 

(Commission

File No.)

 

(IRS Employer

Identification No.)

70 St. Stephen’s Green, Dublin, D02 E2X4, Ireland

(Address of principal executive offices)

Registrant’s telephone number, including area code: - 011-353-1772-2100

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange
on which registered

Ordinary shares, nominal value $0.0001 per share   HZNP   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 


Item 2.02 Results of Operations and Financial Condition.

On May 4, 2022, Horizon Therapeutics plc (the “Company”, “we”, “us” or “our”) issued a press release announcing its financial results for the first quarter ended March 31, 2022. A copy of this press release is attached hereto as Exhibit 99.1.

The information in this Item 2.02 and the exhibit hereto are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On April 28, 2022, Miles W. McHugh notified the Company of his intention to retire from his position as the Company’s Senior Vice President, Chief Accounting Officer, effective as of November 11, 2022, and continue as an advisor to the Company afterwards.

(c) Also on April 28, 2022, in connection with the announcement of Mr. McHugh’s retirement, our Board of Directors appointed Patrick McIlvenny as (i) our Senior Vice President, Deputy Chief Accounting Officer, effective May 5, 2022, and (ii) as our Senior Vice President, Chief Accounting Officer, and principal accounting officer, effective as of Mr. McHugh’s retirement on November 11, 2022.

Mr. McIlvenny, age 43, joined the Company in February 2015 as Vice President, Corporate Controller. Before joining the Company, Mr. McIlvenny served as Group Head of Corporate Reporting at Ardagh Group S.A. between 2013 and 2015, and in various finance roles of increasing responsibilities at Elan Corporation plc from 2005 to 2013. Prior to joining Elan, Mr. McIlvenny worked with PricewaterhouseCoopers and with Deloitte. Mr. McIlvenny is a Fellow of the Institute of Chartered Accountants in England and Wales and earned a Bachelor of Business Studies from the University of Ulster.

Mr. McIlvenny has no family relationship with any of the officers or directors of the Company and has not been party to any transactions with the Company during the past fiscal year to the present that would require reporting pursuant to Item 404(a) of Regulation S-K. There is no arrangement or understanding between Mr. McIlvenny and any third party pursuant to which he was selected as Senior Vice President, Chief Accounting Officer.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit No.   

Description

99.1    Press Release of Horizon Therapeutics plc, dated May 4, 2022. 
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: May 4, 2022

   

HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY

   

By:

 

/s/ Paul W. Hoelscher

     

Paul W. Hoelscher

     

Executive Vice President and Chief Financial Officer

EX-99.1

Exhibit 99.1

 

LOGO

 

Horizon Therapeutics plc Reports First-Quarter 2022 Financial Results

First-Quarter 2022 Results:

— Net Sales of $885.2 Million —

— GAAP Net Income of $204.3 Million; Adjusted EBITDA of $371.2 Million —

— TEPEZZA® (teprotumumab-trbw) Net Sales of $501.5 Million —

— KRYSTEXXA® (pegloticase injection) Net Sales of $140.7 Million —

— Cash Position of $1.64 Billion as of March 31, 2022 —

 

Full-Year 2022 Guidance:

— Maintaining Full-Year 2022 Net Sales Guidance of $3.9 Billion to $4.0 Billion,

Representing 22% Growth at the Midpoint —

— Maintaining Full-Year 2022 Adjusted EBITDA Guidance of $1.63 Billion to $1.70 Billion,

Representing 30% Growth and 230 Basis Points of Margin Expansion at the Midpoint —

— Continue to Expect TEPEZZA Net Sales Percentage Growth in the Mid-30s

— Continue to Expect KRYSTEXXA Net Sales Growth of More Than 20% —

 

Recent Company Highlights:

— U.S. FDA Granted Priority Review of the Company’s Supplemental Biologics License Application (sBLA)

for Co-Treatment of KRYSTEXXA Plus Methotrexate with a July 7, 2022 PDUFA Action Date —

— European Commission Approved UPLIZNA® (inebilizumab-cdon) for the

Treatment of Adult Patients with NMOSD —

— Initiated Launch Preparations to Support Potential Approvals for TEPEZZA and

UPLIZNA in Brazil as part of Global Expansion Strategy —

— Initiated Two Clinical Trials to Date, Five Additional Trials Expected to Initiate this Year —

— Announced Positive Topline Data from Phase 2 Trial Evaluating Dazodalibep (HZN-4920) in Patients

with Rheumatoid Arthritis (RA); Study Met Primary Endpoint and Dazodalibep was Well Tolerated —

DUBLIN May 4, 2022 – Horizon Therapeutics plc (Nasdaq: HZNP) today announced first-quarter 2022 financial results and maintained its full-year 2022 net sales and adjusted EBITDA guidance.

“Our first quarter financial and operational performance established a strong start to the year, with meaningful progress on our strategic priorities and positioning us well for another year of top-tier growth,” said Tim Walbert, chairman, president and chief executive officer, Horizon. “We advanced our pipeline with the initiation of two clinical trials, drove strong performance of our key growth drivers, TEPEZZA, KRYSTEXXA and UPLIZNA, and continued our international expansion. In addition, the FDA granted priority review of our sBLA to expand the KRYSTEXXA label to include co-treatment of KRYSTEXXA plus methotrexate, marking an important milestone in our journey to help more uncontrolled gout patients benefit from the medicine.”


LOGO

 

Financial Highlights

 

(in millions except for per share amounts and percentages)    Q1 22      Q1 21(1)      %
Change
 

Net sales

   $ 885.2      $ 342.4        159  

Net income (loss)

     204.3        (123.4      NM  

Non-GAAP net income

     315.8        4.8        NM  

Adjusted EBITDA

     371.2        42.8        767  

Earnings (loss) per share - diluted

     0.87        (0.55      NM  

Non-GAAP earnings per share - diluted

     1.34        0.02        NM  

 

(1)

First-quarter 2021 results were negatively impacted by a short-term TEPEZZA supply disruption due to U.S. government-mandated COVID 19-vaccine orders.

First Quarter and Recent Company Highlights

 

   

FDA Granted Priority Review of sBLA for Co-Treatment of KRYSTEXXA Plus Methotrexate: In March, the U.S. Food and Drug Administration (FDA) granted priority review of the Company’s sBLA to expand the label for KRYSTEXXA to include co-treatment with methotrexate. The Company submitted an sBLA in January based on results from the MIRROR Phase 4 randomized placebo-controlled trial which demonstrated that 71% of patients receiving KRYSTEXXA plus methotrexate achieved a complete response, a more than 30 percentage-point improvement compared to patients who were randomized to receive KRYSTEXXA plus placebo (p<0.0001). An updated label would allow the Company’s commercial team to promote KRYSTEXXA plus methotrexate to physicians. The Prescription Drug User Fee Act (PDUFA) action date is July 7, 2022.

 

   

UPLIZNA Approved in Europe and China for NMOSD: In April, the European Commission approved UPLIZNA for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are Anti-Aquaporin-4 Immunoglobulin G Seropositive (AQP4-IgG+). Germany is expected to be the first country where the Company initiates promotional and commercialization efforts in the EU. In March, the Company’s strategic partner Hansoh Pharmaceutical Group Company Limited received approval of UPLIZNA for the treatment of NMOSD from the National Medical Products Administration of the People’s Republic of China.

 

   

Advancing the Companys Global Expansion with TEPEZZA and UPLIZNA Launch Preparations in Brazil: The Company initiated its build-out of primary infrastructure in Brazil to support the potential approvals of TEPEZZA for thyroid eye disease (TED) and UPLIZNA for NMOSD. There are no on-label treatments that are commercially available for TED or NMOSD in Brazil. Brazil marks the newest market that the company is pursuing as part of its global expansion strategy.

 

2


LOGO

 

   

Initiated Enrollment in Two Clinical Trials:

 

   

In January, the first patient enrolled in a pivotal Phase 2b trial to evaluate HZN-825 in patients with idiopathic pulmonary fibrosis (IPF), the most common form of interstitial lung disease. IPF is a rare, progressive lung disease caused by inflammation and fibrosis, or scarring, of the lungs.

 

   

In February, the first patient enrolled in a Phase 3 trial in Japan to evaluate TEPEZZA in patients with moderate-to-severe active TED, a serious, progressive and potentially vision-threatening rare autoimmune disease. TEPEZZA has not been approved for commercial use in Japan.

 

   

Announced Positive Topline Proof-of-Concept Data from Dazodalibep Rheumatoid Arthritis Trial: In May, the Company announced positive topline results from the Phase 2 randomized placebo-controlled trial of dazodalibep in patients with RA. The primary endpoint of the trial was met across all doses, a statistically significant change from baseline in DAS28-CRP, a standardized measure of disease activity in RA trials, at Day 113. In addition, dazodalibep was well tolerated across all doses. The impact observed after various doses will inform the dosing regimen for other studies with dazodalibep.

 

   

Presented New UPLIZNA Data at Key Medical Meetings: In April, multiple new data were presented at the American Academy of Neurology (AAN) 2022 Annual Meeting, including new data from the Phase 3 trial showing no significant differences in attacks or Expanded Disability Status Scale (EDSS) worsening between NMOSD patients treated with UPLIZNA with one pre-study attack and those with two or more pre-study attacks. A separate new analysis of the Phase 3 trial showed long-term treatment with UPLIZNA improved pain and quality of life outcomes for at least three years. Additionally, new data from the Phase 3 trial were presented at the 48th Annual Meeting of the North American Neuro-Ophthalmology Society (NANOS 2022) in February, showing that treatment with UPLIZNA effectively reduced the severity of attacks in patients with NMOSD.

 

   

Presented New TEPEZZA Data at Key Medical Meeting: In February, multiple new data were presented at NANOS 2022, including new data from a post-marketing safety analysis of hearing-related events associated with TEPEZZA. Among the thousands of patients included in the analysis, approximately 10% of all cases reported to the safety database included a hearing-related event. This rate was similar to the rate in the Company’s initial trials. The majority of hearing-related adverse events in the pivotal trials and post-approval have been mild to moderate and reversible. No new safety concerns were observed in the post-marketing safety analysis.

 

   

New TEPEZZA Chronic TED Data Published: In January, new data from an independent physician case study of six chronic TED patients who showed benefit after treatment with TEPEZZA were published in Eye, the official journal for the Royal College of Ophthalmologists. The case study adds to the growing body of evidence supporting the use of TEPEZZA in chronic TED patients, with nearly 60 chronic TED patients across multiple case studies who have demonstrated benefit.

 

3


LOGO

 

   

Expanding East Coast R&D and Technical Operations Hub: In January, the Company announced it entered into an agreement to lease a new 192,000-square-foot, state-of-the-art facility under construction in Rockville, Maryland that will serve as the Company’s primary East Coast research and development and technical operations hub. The Company is significantly expanding and consolidating its East Coast footprint with the new facility, nearly quadrupling its current Maryland footprint acquired in the 2021 acquisition of Viela. The Company anticipates adding key R&D talent to support its growing research and development capabilities and expanded pipeline.

 

   

Received Multiple Best Workplace Awards: In April, the Company was named one of Fortune’s “100 Best Companies to Work For®” for the second consecutive year, retaining the highest ranked position in the biotechnology/pharmaceutical category. In March, Great Place to Work Ireland recognized Horizon as one of the “Best Workplaces in Ireland 2022” for the third consecutive year. These recognitions add to the many workplace awards the Company has received, reflecting the high level of engagement of its employees.

 

   

New President, Global Commercial Operations: The Company announced today that Jacopo Leonardi will join Horizon as president, global commercial operations, reporting to Tim Walbert, chairman, president and chief executive officer, effective May 16, 2022. Leonardi is an accomplished life sciences executive with more than two decades of commercial experience, which includes commercial launch, R&D new product planning as well as accelerating growth for high performing businesses in rare disease and immunology. Leonardi will oversee the U.S. and international commercial organizations, commercial development (life-cycle management) and global medical affairs.

Key Clinical Development Programs

 

   

Daxdilimab (HZN-7734), an anti-ILT7 human monoclonal antibody that depletes certain dendritic cells. Depleting these cells may interrupt the cycle of inflammation that causes tissue damage in diseases such as lupus, and a variety of other autoimmune conditions.

 

   

Systemic Lupus Erythematosus (SLE) Trial: Phase 2 randomized placebo-controlled trial underway to evaluate daxdilimab in patients with SLE, a disease in which the body’s immune system attacks its own tissues and organs.

 

   

Alopecia Areata Trial: Phase 2 trial to evaluate daxdilimab in patients with alopecia areata, an autoimmune disorder characterized by nonscarring hair loss, expected to initiate in the second quarter of 2022.

 

   

Discoid Lupus Erythematosus (DLE) Trial: Phase 2 trial to evaluate daxdilimab in patients with DLE, a rare, chronic, inflammatory skin condition characterized by lesions that result in scarring, expected to initiate by mid-year 2022.

 

   

Lupus Nephritis Trial: Phase 2 trial to evaluate daxdilimab in patients with lupus nephritis, a rare, autoimmune and inflammatory condition of the kidney, expected to initiate in the third quarter of 2022.

 

   

Dermatomyositis Trial: Phase 2 trial to evaluate daxdilimab in patients with dermatomyositis, a rare, autoimmune disorder characterized by rashes, debilitating muscle weakness and interstitial lung disease, expected to initiate in the fourth quarter of 2022.

 

4


LOGO

 

   

Dazodalibep (HZN-4920), a CD40 ligand antagonist that blocks T-cell interaction with CD40-expressing B-cells, disrupting the overactivation of the CD40 ligand co-stimulatory pathway. Several autoimmune diseases are associated with the overactivation of this pathway.

 

   

Sjögren’s Syndrome Trial: Phase 2 randomized placebo-controlled trial underway to evaluate dazodalibep in patients with Sjögren’s syndrome, a chronic, systemic autoimmune condition that impacts exocrine glands, including the salivary and tear glands. The trial completed enrollment in April 2022.

 

   

Rheumatoid Arthritis Trial: Phase 2 randomized placebo-controlled trial to evaluate dazodalibep in patients with RA. Topline results were announced in May 2022. The trial met the primary endpoint and dazodalibep was well tolerated.

 

   

Kidney Transplant Rejection Trial: Phase 2 open-label trial underway to evaluate dazodalibep in kidney transplant rejection patients.

 

   

Focal Segmental Glomerulosclerosis (FSGS) Trial: Phase 2 trial to evaluate dazodalibep in patients with FSGS, a rare kidney disorder characterized by scarring of glomeruli, expected to initiate in the fourth quarter of 2022.

 

   

HZN-825, an oral lysophosphatidic acid receptor 1 (LPAR1) antagonist designed to prevent gene activation.

 

   

Diffuse Cutaneous Systemic Sclerosis Trial: Pivotal Phase 2b trial underway to evaluate HZN-825 in diffuse cutaneous systemic sclerosis.

 

   

Idiopathic Pulmonary Fibrosis Trial: Pivotal Phase 2b trial initiated in January 2022 to evaluate HZN-825 in idiopathic pulmonary fibrosis, the most common form of interstitial lung disease.

 

   

UPLIZNA, an anti-CD19 humanized monoclonal antibody that depletes B-cells, including the pathogenic cells that produce autoantibodies.

 

   

Myasthenia Gravis Trial: Phase 3 randomized placebo-controlled trial underway to evaluate UPLIZNA in patients with myasthenia gravis, a chronic, rare, autoimmune neuromuscular disease that affects voluntary muscles, especially those that control the eyes, mouth, throat and limbs.

 

   

IgG4-Related Disease Trial: Phase 3 randomized placebo-controlled trial underway to evaluate UPLIZNA in patients with IgG4-related disease, which is a group of disorders marked by tumor-like swelling and fibrosis of affected organs, such as the pancreas, salivary glands and kidneys.

 

   

TEPEZZA, an insulin-like growth factor type 1 receptor (IGF-1R) antagonist monoclonal antibody.

 

   

Chronic TED Trial: Phase 4 randomized placebo-controlled trial underway to evaluate TEPEZZA in chronic TED.

 

   

TED in Japan (OPTIC-J) Trial: Phase 3 randomized placebo-controlled trial in Japan initiated in February 2022 to evaluate TEPEZZA in patients with moderate-to-severe active TED.

 

5


LOGO

 

   

Subcutaneous (SC) Administration Trial: Phase 1b trial to explore the pharmacokinetics, safety, tolerability, efficacy and immunogenicity of subcutaneous administration of TEPEZZA in patients with TED, expected to initiate by mid-year 2022.

 

   

Diffuse Cutaneous Systemic Sclerosis Exploratory Trial: Phase 1 exploratory trial underway to evaluate TEPEZZA in diffuse cutaneous systemic sclerosis.

 

   

KRYSTEXXA, a recombinant uricase enzyme that converts urate into a water-soluble liquid, allantoin, that can be easily excreted from the body.

 

   

Shorter Infusion Duration Trial: Phase 4 open-label trial underway to evaluate the impact of administering KRYSTEXXA plus methotrexate over a shorter infusion duration in patients with uncontrolled gout.

 

   

Monthly Dosing Trial: Phase 4 open-label trial underway to evaluate monthly dosing of KRYSTEXXA plus methotrexate in patients with uncontrolled gout.

 

   

Retreatment Trial: Phase 4 open-label trial underway to evaluate KRYSTEXXA plus methotrexate in patients who were not complete responders to KRYSTEXXA monotherapy.

 

   

HZN-1116, a fully human monoclonal antibody designed to bind and neutralize the function of the FLT3-ligand, thereby reducing both conventional and plasmacytoid dendritic cells.

 

   

Autoimmune Disease Trial: Phase 1 trial underway to evaluate HZN-1116 in patients with autoimmune diseases.

First-Quarter Financial Results

Note: For additional detail and reconciliation of non-GAAP financial measures to the most directly comparable GAAP financial measures, please refer to the tables at the end of this release.

 

   

Net Sales: First-quarter 2022 net sales were $885.2 million, an increase of 159% compared to the first quarter of 2021. First-quarter 2021 results were negatively impacted by a short-term TEPEZZA supply disruption due to U.S. government-mandated COVID 19-vaccine orders.

 

   

Gross Profit: Under U.S. GAAP, the first-quarter 2022 gross profit ratio was 75.7% compared to 70.7% in the first quarter of 2021. The non-GAAP gross profit ratio in the first quarter of 2022 was 88.9% compared to 90.9% in the first quarter of 2021.

 

   

Operating Expenses: R&D expenses were 11.7% of net sales and SG&A expenses were 42.1% of net sales in the first quarter of 2022. First-quarter non-GAAP R&D expenses were 10.4% of net sales and non-GAAP SG&A expenses were 37.1% of net sales.

 

   

Income Tax Expense (Benefit): On a GAAP basis in the first quarter of 2022, income tax benefit was $31.5 million. First-quarter non-GAAP income tax expense was $35.7 million.

 

   

Net Income: In the first-quarter of 2022, net income on a GAAP and non-GAAP basis was $204.3 million and $315.8 million, respectively.

 

   

Adjusted EBITDA: First-quarter 2022 adjusted EBITDA was $371.2 million.

 

6


LOGO

 

   

Earnings (Loss) per Share: On a GAAP basis, diluted earnings (loss) per share in the first quarter of 2022 and 2021 were $0.87 and $(0.55). Non-GAAP diluted earnings per share in the first quarter of 2022 and 2021 were $1.34 and $0.02, respectively. Weighted average shares outstanding used for calculating GAAP and non-GAAP diluted earnings per share in the first quarter of 2022 were 236.0 million.

First-Quarter Segment Results

Management uses net sales and segment operating income to evaluate the performance of the Company’s two segments, the orphan segment and the inflammation segment. While segment operating income contains certain adjustments to the directly comparable GAAP figures in the Company’s consolidated financial results, such as the exclusion of upfront and milestone payments related to license and collaboration agreements, it is considered to be prepared in accordance with GAAP for purposes of presenting the Company’s segment operating results.

Orphan Segment

 

(in millions except for percentages)    Q1 22      Q1 21      %
Change
 

TEPEZZA®(1)

   $ 501.5      $ 2.1        NM  

KRYSTEXXA®

     140.7        106.7        32  

RAVICTI®

     78.3        72.8        7  

PROCYSBI®

     49.6        43.4        14  

ACTIMMUNE®

     31.3        28.8        9  

UPLIZNA®(2)

     30.5        1.8        NM  

BUPHENYL®

     2.2        1.7        30  

QUINSAIRTM

     0.3        0.2        41  
  

 

 

    

 

 

    

Orphan Net Sales

   $ 834.4      $ 257.5        224  
  

 

 

    

 

 

    

Orphan Segment Operating Income

   $ 351.5      $ 1.1        NM  

 

  (1)

First-quarter 2021 results were negatively impacted by a short-term TEPEZZA supply disruption due to U.S. government-mandated COVID 19-vaccine orders.

  (2)

UPLIZNA was acquired on March 15, 2021. First-quarter 2022 UPLIZNA net sales included $5.2 million in revenue and milestone payments from the Company’s international partners.

 

   

First-quarter 2022 net sales of the orphan segment, the Company’s strategic growth segment, were $834.4 million, driven by the strong performance of TEPEZZA, KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE and UPLIZNA. First-quarter 2022 orphan segment operating income was $351.5 million.

 

7


LOGO

 

Inflammation Segment

 

(in millions except for percentages)    Q1 22      Q1 21      %
Change
 

PENNSAID 2%®

   $ 35.4      $ 45.8        (23

RAYOS®

     13.5        15.3        (12

DUEXIS®(1)

     1.1        19.5        (94

VIMOVO®

     0.9        4.3        (79
  

 

 

    

 

 

    

Inflammation Net Sales

   $ 50.9      $ 84.9        (40
  

 

 

    

 

 

    

Inflammation Segment Operating Income

   $ 15.3      $ 42.7        (64

 

  (1)

On Aug. 4, 2021, Alkem Laboratories, Inc. initiated an at-risk launch of generic DUEXIS in the United States.

 

First-quarter 2022 net sales of the inflammation segment were $50.9 million and segment operating income was $15.3 million.

Cash Flow Statement and Balance Sheet Highlights

 

First-quarter 2022 operating cash flow on a GAAP and non-GAAP basis was $215.8 million and $222.6 million, respectively.

 

As of March 31, 2022, the Company had cash and cash equivalents of $1.64 billion.

 

As of March 31, 2022, the total principal amount of debt outstanding was $2.60 billion.

2022 Guidance

The Company continues to expect full-year 2022 net sales to range between $3.9 billion and $4.0 billion, representing 22% growth at the midpoint. The Company continues to expect TEPEZZA full-year 2022 net sales percentage growth in the mid-30s and KRYSTEXXA full-year 2022 net sales growth of more than 20%. The Company continues to expect full-year 2022 adjusted EBITDA to range between $1.63 billion and $1.70 billion, representing 30% growth and 230 basis points of margin expansion at the midpoint.

Webcast

At 8 a.m. EDT / 1 p.m. IST today, the Company will host a live webcast to review its financial and operating results and provide a general business update. The live webcast and a replay may be accessed at http://ir.horizontherapeutics.com. Please connect to the Company’s website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. A replay of the webcast will be available approximately two hours after the live webcast.

 

8


LOGO

 

About Horizon

Horizon is focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Our pipeline is purposeful: We apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, visit www.horizontherapeutics.com and follow us on Twitter, LinkedIn, Instagram and Facebook.

Note Regarding Use of Non-GAAP Financial Measures

Horizon provides certain non-GAAP financial measures, including EBITDA, or earnings before interest, taxes, depreciation and amortization, adjusted EBITDA, non-GAAP net income, non-GAAP diluted earnings per share, non-GAAP gross profit and gross profit ratio, non-GAAP operating expenses, non-GAAP operating income, non-GAAP tax benefit (expense) and tax rate, non-GAAP operating cash flow and certain other non-GAAP income statement line items, each of which include adjustments to GAAP figures. These non-GAAP measures are intended to provide additional information on Horizon’s performance, operations, expenses, profitability and cash flows. Adjustments to Horizon’s GAAP figures exclude acquisition and/or divestiture-related costs, manufacturing plant start-up costs, restructuring and realignment costs and litigation settlements, as well as non-cash items such as share-based compensation, inventory step-up expense, depreciation and amortization, non-cash interest expense, long-lived assets impairment charges, gain (loss) on equity security investments and other non-cash adjustments. Certain other special items or substantive events may also be included in the non-GAAP adjustments periodically when their magnitude is significant within the periods incurred. Horizon maintains an established non-GAAP cost policy that guides the determination of what costs will be excluded in non-GAAP measures. Horizon believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of Horizon’s financial and operating performance. The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of the Company’s historical and expected financial results and trends and to facilitate comparisons between periods and with respect to projected information. In addition, these non-GAAP financial measures are among the indicators Horizon’s management uses for planning and forecasting purposes and measuring the Company’s performance. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, non-GAAP financial measures used by other companies. Horizon has not provided a reconciliation of its full-year 2022 adjusted EBITDA and associated margin expansion outlook to an expected net income (loss) outlook because certain items such as acquisition/divestiture-related expenses and share-based compensation that are a component of net income (loss) cannot be reasonably projected due to the significant impact of changes in Horizon’s stock price, the variability associated with the size or timing of acquisitions/divestitures and other factors. These components of net income (loss) could significantly impact Horizon’s actual net income (loss) and margins.

 

9


LOGO

 

Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements related to Horizon’s full-year 2022 net sales, adjusted EBITDA and margin expansion guidance; expected financial performance and operating results in future periods, including potential growth in net sales of certain of Horizon’s medicines; development, manufacturing and commercialization plans; expected timing of clinical trials, availability of clinical data and regulatory submissions; potential market opportunities for, and benefits of, Horizon’s medicines and medicine candidates and business and other statements that are not historical facts. These forward-looking statements are based on Horizon’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks that Horizon’s actual future financial and operating results may differ from its expectations or goals; Horizon’s ability to grow net sales from existing medicines; impacts of the COVID-19 pandemic and actions taken to slow its spread, including impacts on supplies and net sales of Horizon’s medicines and potential delays in clinical trials; impacts of the on-going war between Russia and Ukraine; the fact that Horizon’s full-year 2022 net sales, adjusted EBITDA and TEPEZZA net sales guidance and the expected timing of certain TEPEZZA clinical trials assume that future committed manufacturing slots for TEPEZZA are not cancelled and are run successfully, which could be impacted by additional government-mandated COVID-19 vaccine production orders and other risks associated with the manufacture of biologic medicines; risks associated with acquisitions, such as the risk that the businesses will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the transaction will not occur; the availability of coverage and adequate reimbursement and pricing from government and third-party payers; risks relating to Horizon’s ability to successfully implement its business strategies, including its manufacturing and global expansion strategy; risks inherent in developing novel medicine candidates and existing medicines for new indications; risks associated with regulatory approvals; risks in the ability to recruit, train and retain qualified personnel; competition, including potential generic competition; the ability to protect intellectual property and defend patents; regulatory obligations and oversight, including any changes in the legal and regulatory environment in which Horizon operates and those risks detailed from time-to-time under the caption “Risk Factors” and elsewhere in Horizon’s filings and reports with the SEC. Horizon undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information.

 

Contacts:      
Investors:    U.S. Media:   
Tina Ventura    Geoff Curtis   
Senior Vice President,    Executive Vice President,            
Chief Investor Relations Officer    Corporate Affairs & Chief Communications Officer   
investor-relations@horizontherapeutics.com    media@horizontherapeutics.com   
Erin Linnihan    Ireland Media:   
Executive Director,    Ray Gordon   
Investor Relations    Gordon MRM   
investor-relations@horizontherapeutics.com    ray@gordonmrm.ie   
Ruth Venning      
Executive Director,      
Investor Relations and ESG      
investor-relations@horizontherapeutics.com      

 

10


LOGO

 

Horizon Therapeutics plc

Condensed Consolidated Statements of Operations (Unaudited)

(in thousands, except share and per share data)

 

     Three Months Ended March 31,  
     2022     2021  

Net sales

   $ 885,245     $ 342,406  

Cost of goods sold

     215,062       100,368  
  

 

 

   

 

 

 

Gross profit

     670,183       242,038  
  

 

 

   

 

 

 

OPERATING EXPENSES:

    

Research and development

     103,132       57,693  

Selling, general and administrative

     372,734       331,992  

Impairment of long-lived asset

     —         12,371  
  

 

 

   

 

 

 

Total operating expenses

     475,866       402,056  
  

 

 

   

 

 

 

Operating income (loss)

     194,317       (160,018
  

 

 

   

 

 

 

OTHER EXPENSE, NET:

    

Interest expense, net

     (21,256     (13,460

Foreign exchange gain (loss)

     420       (848

Other (expense) income, net

     (742     3,224  
  

 

 

   

 

 

 

Total other expense, net

     (21,578     (11,084
  

 

 

   

 

 

 

Income (loss) before benefit for income taxes

     172,739       (171,102

Benefit for income taxes

     (31,522     (47,751
  

 

 

   

 

 

 

Net income (loss)

   $ 204,261     $ (123,351
  

 

 

   

 

 

 

Net income (loss) per ordinary share - basic

   $ 0.89     $ (0.55
  

 

 

   

 

 

 

Weighted average ordinary shares outstanding - basic

     229,094,311       223,920,768  
  

 

 

   

 

 

 

Net income (loss) per ordinary share - diluted

   $ 0.87     $ (0.55
  

 

 

   

 

 

 

Weighted average ordinary shares outstanding - diluted

     235,953,318       223,920,768  
  

 

 

   

 

 

 

 

11


LOGO

 

Horizon Therapeutics plc

Condensed Consolidated Balance Sheets (Unaudited)

(in thousands, except share data)

 

     As of  
     March 31,
2022
    December 31,
2021
 
              

ASSETS

  

CURRENT ASSETS:

    

Cash and cash equivalents

   $ 1,643,129     $ 1,580,317  

Restricted cash

     4,136       3,839  

Accounts receivable, net

     684,507       632,775  

Inventories, net

     226,524       225,730  

Prepaid expenses and other current assets

     389,435       357,106  
  

 

 

   

 

 

 

Total current assets

     2,947,731       2,799,767  
  

 

 

   

 

 

 

Property, plant and equipment, net

     295,147       292,298  

Developed technology and other intangible assets, net

     2,871,979       2,960,118  

In-process research and development

     880,000       880,000  

Goodwill

     1,066,709       1,066,709  

Deferred tax assets, net

     516,317       538,098  

Other assets

     162,455       140,738  
  

 

 

   

 

 

 

Total assets

   $ 8,740,338     $ 8,677,728  
  

 

 

   

 

 

 

LIABILITIES AND SHAREHOLDERS’ EQUITY

    

CURRENT LIABILITIES:

    

Accounts payable

   $ 67,014     $ 30,125  

Accrued expenses and other current liabilities

     377,433       523,015  

Accrued trade discounts and rebates

     364,732       317,431  

Long-term debt—current portion

     16,000       16,000  
  

 

 

   

 

 

 

Total current liabilities

     825,179       886,571  
  

 

 

   

 

 

 

LONG-TERM LIABILITIES:

    

Long-term debt, net

     2,552,741       2,555,233  

Deferred tax liabilities, net

     334,778       390,455  

Other long-term liabilities

     209,811       173,076  
  

 

 

   

 

 

 

Total long-term liabilities

     3,097,330       3,118,764  
  

 

 

   

 

 

 

COMMITMENTS AND CONTINGENCIES

    

SHAREHOLDERS’ EQUITY:

    

Ordinary shares, $0.0001 nominal value; 600,000,000 shares authorized at March 31, 2022 and December 31, 2021; 229,873,900 and 227,760,936 shares issued at March 31, 2022 and December 31, 2021, respectively; and 229,489,534 and 227,376,570 shares outstanding at March 31, 2022 and December 31, 2021, respectively

     23       23  

Treasury stock, 384,366 ordinary shares at March 31, 2022 and December 31, 2021

     (4,585     (4,585

Additional paid-in capital

     4,314,647       4,373,337  

Accumulated other comprehensive loss

     (15,122     (14,987

Retained earnings

     522,866       318,605  
  

 

 

   

 

 

 

Total shareholders’ equity

     4,817,829       4,672,393  
  

 

 

   

 

 

 

Total liabilities and shareholders’ equity

   $ 8,740,338     $ 8,677,728  
  

 

 

   

 

 

 

 

12


LOGO

 

Horizon Therapeutics plc

Condensed Consolidated Statements of Cash Flows (Unaudited)

(in thousands)

 

     Three Months Ended
March 31,
 
     2022     2021  

CASH FLOWS FROM OPERATING ACTIVITIES:

    

Net income (loss)

   $ 204,261     $ (123,351

Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:

    

Depreciation and amortization expense

     95,112       70,820  

Equity-settled share-based compensation

     47,300       61,166  

Acquired in-process research and development expense

     2,000       —    

Impairment of long-lived asset

     —         12,371  

Amortization of debt discount and deferred financing costs

     1,577       773  

Deferred income taxes

     (33,896     (28,771

Foreign exchange and other adjustments

     1,190       (5,440

Changes in operating assets and liabilities:

    

Accounts receivable

     (51,665     224,575  

Inventories

     (785     (13,660

Prepaid expenses and other current assets

     (33,205     (65,575

Accounts payable

     36,067       993  

Accrued trade discounts and rebates

     47,279       (28,736

Accrued expenses and other current liabilities

     (113,775     (111,963

Other non-current assets and liabilities

     14,331       3,070  
  

 

 

   

 

 

 

Net cash provided by (used in) operating activities

     215,791       (3,728
  

 

 

   

 

 

 

CASH FLOWS FROM INVESTING ACTIVITIES:

    

Purchases of property, plant and equipment

     (14,198     (18,333

Receipts (payments) for long-term investments, net

     1,596       (3,808

Payments for acquisitions, net of cash acquired

     (3,122     (2,707,358

Payment related to license agreement

     (25,000     —    
  

 

 

   

 

 

 

Net cash used in investing activities

     (40,724     (2,729,499
  

 

 

   

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES:

    

Repayment of term loans

     (4,000     —    

Net proceeds from term loans

     —         1,577,612  

Proceeds from the issuance of ordinary shares in connection with stock option exercises

     9,071       19,843  

Payment of employee withholding taxes relating to share-based awards

     (115,108     (128,261
  

 

 

   

 

 

 

Net cash (used in) provided by financing activities

     (110,037     1,469,194  
  

 

 

   

 

 

 

Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash

     (1,921     (3,998
  

 

 

   

 

 

 

Net increase (decrease) in cash, cash equivalents and restricted cash

     63,109       (1,268,031

Cash, cash equivalents and restricted cash, beginning of the period(1)

     1,584,156       2,083,479  
  

 

 

   

 

 

 

Cash, cash equivalents and restricted cash, end of the period(1)

   $ 1,647,265     $ 815,448  
  

 

 

   

 

 

 

 

(1)

Amounts include restricted cash balance in accordance with ASU No. 2016-18. Cash and cash equivalents excluding restricted cash are shown on the balance sheet.

 

13


LOGO

 

Horizon Therapeutics plc

GAAP to Non-GAAP Reconciliations

Net Income and Earnings Per Share (Unaudited)

(in thousands, except share and per share data)

 

     Three Months Ended March 31,  
     2022     2021  

GAAP net income (loss)

   $ 204,261     $ (123,351

Non-GAAP adjustments:

    

Acquisition/divestiture-related costs

     1,589       49,108  

Loss on equity security investments

     4,646       —    

Restructuring and realignment costs

     537       6,093  

Manufacturing plant start-up costs

     807       —    

Amortization and step-up:

    

Intangible amortization expense

     89,260       66,369  

Inventory step-up expense

     27,201       911  

Amortization of debt discount and deferred financing costs

     1,577       773  

Impairment of long-lived asset

     —         12,371  

Share-based compensation

     47,300       61,166  

Depreciation

     5,852       4,451  
  

 

 

   

 

 

 

Total of pre-tax non-GAAP adjustments

     178,769       201,242  

Income tax effect of pre-tax non-GAAP adjustments

     (67,212     (73,129
  

 

 

   

 

 

 

Total of non-GAAP adjustments

     111,557       128,113  
  

 

 

   

 

 

 

Non-GAAP net income

   $ 315,818     $ 4,762  
  

 

 

   

 

 

 

Non-GAAP Earnings Per Share:

    

Weighted average ordinary shares - Basic

     229,094,311       223,920,768  
  

 

 

   

 

 

 

Non-GAAP Earnings Per Share - Basic:

    

GAAP earnings (loss) per share - Basic

   $ 0.89     $ (0.55

Non-GAAP adjustments

     0.49       0.57  
  

 

 

   

 

 

 

Non-GAAP earnings per share - Basic

   $ 1.38     $ 0.02  
  

 

 

   

 

 

 

Weighted average ordinary shares - Diluted

    

Weighted average ordinary shares - Basic

     229,094,311       223,920,768  

Ordinary share equivalents

     6,859,007       10,190,012  
  

 

 

   

 

 

 

Weighted average ordinary shares - Diluted

     235,953,318       234,110,780  
  

 

 

   

 

 

 

Non-GAAP Earnings Per Share - Diluted

    

GAAP earnings (loss) per share - Diluted

   $ 0.87     $ (0.55

Non-GAAP adjustments

     0.47       0.57  
  

 

 

   

 

 

 

Non-GAAP earnings per share - Diluted

   $ 1.34     $ 0.02  
  

 

 

   

 

 

 

 

14


LOGO

 

Horizon Therapeutics plc

GAAP to Non-GAAP Reconciliations

EBITDA and Adjusted EBITDA (Unaudited)

(in thousands)

 

     Three Months Ended
March 31,
 
     2022     2021  

GAAP net income (loss)

   $ 204,261     $ (123,351

Depreciation

     5,852       4,451  

Amortization and step-up:

    

Intangible amortization expense

     89,260       66,369  

Inventory step-up expense

     27,201       911  

Interest expense, net (including amortization of debt discount and deferred financing costs)

     21,256       13,460  

Benefit for income taxes

     (31,522     (47,751
  

 

 

   

 

 

 

EBITDA

   $ 316,308     $ (85,911
  

 

 

   

 

 

 

Other non-GAAP adjustments:

    

Acquisition/divestiture-related costs

     1,589       49,108  

Loss on equity security investments

     4,646       —    

Restructuring and realignment costs

     537       6,093  

Manufacturing plant start-up costs

     807       —    

Impairment of long-lived asset

     —         12,371  

Share-based compensation

     47,300       61,166  
  

 

 

   

 

 

 

Total of other non-GAAP adjustments

     54,879       128,738  
  

 

 

   

 

 

 

Adjusted EBITDA

   $ 371,187     $ 42,827  
  

 

 

   

 

 

 

 

15


LOGO

 

Horizon Therapeutics plc

GAAP to Non-GAAP Reconciliations

Operating Income (Unaudited)

(in thousands)

 

     Three Months Ended March 31,  
     2022      2021  

GAAP operating income (loss)

   $  194,317      $  (160,018

Non-GAAP adjustments:

     

Acquisition/divestiture-related costs

     1,589        49,391  

Restructuring and realignment costs

     537        6,093  

Manufacturing plant start-up costs

     807        —    

Amortization and step-up:

     

Intangible amortization expense

     89,260        66,369  

Inventory step-up expense

     27,201        911  

Impairment of long-lived asset

     —          12,371  

Share-based compensation

     47,300        61,166  

Depreciation

     5,852        4,451  
  

 

 

    

 

 

 

Total of non-GAAP adjustments

     172,546        200,752  
  

 

 

    

 

 

 

Non-GAAP operating income

   $ 366,863      $ 40,734  
  

 

 

    

 

 

 

Foreign exchange gain (loss)

     420        (848

Other income, net

     3,904        2,941  
  

 

 

    

 

 

 

Adjusted EBITDA

   $ 371,187      $ 42,827  
  

 

 

    

 

 

 

 

16


LOGO

 

Horizon Therapeutics plc

GAAP to Non-GAAP Reconciliations

Gross Profit and Operating Cash Flow (Unaudited)

(in thousands, except percentages)

 

     Three Months Ended March 31,  
     2022     2021  

Non-GAAP Gross Profit:

    

GAAP gross profit

   $  670,183     $  242,038  

Non-GAAP gross profit adjustments:

    

Acquisition/divestiture-related costs

     (1,304     205  

Intangible amortization expense

     88,725       66,169  

Inventory step-up expense

     27,201       911  

Share-based compensation

     2,177       1,936  

Depreciation

     56       115  
  

 

 

   

 

 

 

Total of Non-GAAP adjustments

     116,855       69,336  
  

 

 

   

 

 

 

Non-GAAP gross profit

   $ 787,038     $ 311,374  
  

 

 

   

 

 

 

GAAP gross profit %

     75.7     70.7

Non-GAAP gross profit %

     88.9     90.9

GAAP cash provided by (used in) operating activities

   $ 215,791     $ (3,728

Cash payments for acquisition/divestiture-related costs

     4,448       64,192  

Cash payments for restructuring and realignment costs

     574       —    

Cash payments for manufacturing start-up costs

     1,768       —    
  

 

 

   

 

 

 

Non-GAAP operating cash flow

   $ 222,581     $ 60,464  
  

 

 

   

 

 

 

 

17


LOGO

 

Horizon Therapeutics plc

GAAP to Non-GAAP Tax Rate Reconciliation (Unaudited)

(in millions, except percentages and per share amounts)

 

     Q1 2022  
     Pre-tax Net
Income
    Income Tax
(Benefit) Expense
    Tax Rate     Net Income     Diluted Earnings Per
Share
 

As reported - GAAP

   $ 172.7     $  (31.5     (18.2 )%    $ 204.3     $ 0.87  

Non-GAAP adjustments

     178.8       67.2         111.6    
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Non-GAAP

   $ 351.5     $ 35.7       10.2   $ 315.8     $ 1.34  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 
     Q1 2021  
     Pre-tax Net
Income (loss)
    Income Tax
(Benefit) Expense
    Tax Rate     Net Income
(loss)
    Diluted Earnings
(loss) Per Share
 

As reported - GAAP

   $  (171.1   $  (47.8     27.9   $  (123.4   $  (0.55

Non-GAAP adjustments

     201.2       73.1         128.1    
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Non-GAAP

   $ 30.1     $ 25.4       84.2   $ 4.7     $ 0.02  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

18


LOGO

 

Horizon Therapeutics plc

Certain Income Statement Line Items - Non-GAAP Adjusted

For the Three Months Ended March 31, 2022 (Unaudited)

(in thousands)

 

     COGS     Research &
Development
     Selling,
General &
Administrative
     Interest
Expense
     Other
Income, net
     Income Tax
Benefit
(Expense)
 

GAAP as reported

   $  (215,062)     $  (103,132)      $  (372,734)      $  (21,256)      $  (742)      $ 31,522  

Non-GAAP Adjustments:

                

Acquisition/divestiture-related costs(1)

     (1,304     2,001        892        —          —          —    

Loss on equity security investments(2)

     —         —          —          —          4,646        —    

Restructuring and realignment costs(3)

     —         —          537        —          —          —    

Manufacturing plant start-up costs(4)

     —         —          807        —          —          —    

Amortization and step-up:

                

Intangible amortization expense(5)

     88,725       —          535        —          —          —    

Inventory step-up expense(6)

     27,201       —          —          —          —          —    

Amortization of debt discount and deferred financing costs(7)

     —         —          —          1,577        —          —    

Share-based compensation(8)

     2,177       8,976        36,147        —          —          —    

Depreciation(9)

     56       225        5,571        —          —          —    

Income tax effect on pre-tax non-GAAP adjustments(10)

     —         —          —          —          —          (67,212
  

 

 

   

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total of non-GAAP adjustments (12)

     116,855       11,202        44,489        1,577        4,646        (67,212
  

 

 

   

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Non-GAAP (12)

   $ (98,207)     $ (91,930)      $ (328,245)      $ (19,679)      $  3,904      $  (35,690)  
  

 

 

   

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Horizon Therapeutics plc

Certain Income Statement Line Items - Non-GAAP Adjusted

For the Three Months Ended March 31, 2021 (Unaudited)

(in thousands)

 

     COGS      Research &
Development
     Selling, General
& Administrative
     Impairment of
Long-Lived Assets
     Interest
Expense
     Other
Income, net
    Income Tax
Benefit
(Expense)
 

GAAP as reported

   $  (100,368)      $  (57,693)      $  (331,992)      $  (12,371)      $  (13,460)      $  3,224     $ 47,751  

Non-GAAP Adjustments:

                   

Acquisition/divestiture-related costs(1)

     205        3        49,183        —          —          (283     —    

Restructuring and realignment costs(3)

     —          —          6,093        —          —          —         —    

Amortization and step-up:

                   

Intangible amortization expense(5)

     66,169        —          200        —          —          —         —    

Inventory step-up expense(6)

     911        —          —          —          —          —         —    

Amortization of debt discount and deferred financing costs(7)

     —          —          —          —          773        —         —    

Impairment of long lived asset(11)

     —          —          —          12,371        —          —         —    

Share-based compensation(8)

     1,936        5,616        53,614        —          —          —         —    

Depreciation(9)

     115        49        4,287        —          —          —         —    

Income tax effect on pre-tax non-GAAP adjustments(10)

     —          —          —          —          —          —         (73,129
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

   

 

 

 

Total of non-GAAP adjustments (12)

     69,336        5,668        113,377        12,371        773        (283     (73,129
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

   

 

 

 

Non-GAAP (12)

   $ (31,032)      $ (52,025)      $ (218,615)      $ —        $ (12,687)      $ 2,941     $  (25,378)  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

   

 

 

 

 

19


LOGO

 

NOTES FOR CERTAIN INCOME STATEMENT LINE ITEMS - NON-GAAP

 

1.

Primarily represents transaction and integration costs, including, advisory, legal, consulting and certain employee-related costs, incurred in connection with our acquisitions and divestitures. Costs recovered from subleases of acquired facilities and reimbursed expenses incurred under transition arrangements for divestitures are also reflected in this line item.

 

2.

We held investments in equity securities with readily determinable fair values of $8.5 million as of March 31, 2022, which are included in other assets in the condensed consolidated balance sheet. For the three months ended March 31, 2022, we recognized a net unrealized loss of $4.6 million due to the change in fair value of these securities.

 

3.

Represents rent and maintenance charges as a result of vacating the leased Lake Forest office in the first quarter of 2021.

 

4.

During the three months ended March 31, 2022, we recorded $0.8 million of manufacturing plant start-up costs related to the Waterford biologic drug product manufacturing facility purchased from EirGen in July 2021.

 

5.

Intangible amortization expenses are primarily associated with our developed technology related to TEPEZZA, KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, UPLIZNA, BUPHENYL, PENNSAID 2% and RAYOS.

 

6.

During the three months ended March 31, 2022 and 2021, we recognized in cost of goods sold $27.2 million and $0.9 million, respectively, for inventory step-up expense related to UPLIZNA inventory revalued in connection with the Viela acquisition. Because inventory step-up expense is related to an acquisition, will not continue indefinitely and has a significant effect on our gross profit, gross margin percentage and net income for all affected periods, we exclude inventory step-up expense from our non-GAAP financial measures.

 

7.

Represents amortization of debt discount and deferred financing costs associated with our debt.

 

8.

Represents share-based compensation expense associated with our stock option, restricted stock unit and performance stock unit grants to our employees and non-employee directors, and our employee share purchase plan.

 

9.

Represents depreciation expense related to our property, plant, equipment, software and leasehold improvements.

 

10.

Income tax adjustments on pre-tax non-GAAP adjustments represent the estimated income tax impact of each pre-tax non-GAAP adjustment based on the statutory income tax rate of the applicable jurisdictions for each non-GAAP adjustment.

 

11.

During the three months ended March 31, 2021, we recorded a right-of-use asset impairment charge of $12.4 million as a result of vacating the leased Lake Forest office.

 

20


LOGO

 

12.

Following consultation with the staff of the Division of Corporation Finance of the U.S. Securities and Exchange Commission, we no longer exclude upfront and milestone payments related to license and collaboration agreements from our non-GAAP financial measures and its line-item components. Adjusted EBITDA and non-GAAP net income for the three months ended March 31, 2021, includes $3.0 million of upfront and milestone payments related to license and collaboration agreements. These amounts continue to be excluded from our segment operating income and from certain measures contained in our credit agreement that are relevant to, among other things, the calculation of the interest rate.

 

21